Clearside Biomedical

Clearside Biomedical Operating Expenses

Delisted

The Total Operating Expenses of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 30.40 M USD. In the previous year, Total Operating Expenses was 32.72 M USD — a change of -7.09% (lower).

Operating Expenses

30.40 MUSD

YoY

-7.09%

Last updated:

Total Operating Expenses of Clearside Biomedical is 2024 30.40 M USD. Total Operating Expenses of Clearside Biomedical was 2023 32.72 M USD. It decreases by -7.09% lower compared to the previous year.

The Clearside Biomedical Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2017
58.75 M USD
Jan 1, 2018
82.98 M USD
Jan 1, 2019
32.48 M USD
Jan 1, 2020
25.83 M USD
Jan 1, 2021
30.20 M USD
Jan 1, 2022
31.41 M USD
Jan 1, 2023
32.72 M USD
Jan 1, 2024
30.40 M USD
The Clearside Biomedical Operating Expenses history
YEAROperating ExpensesYoY
30.40 MUSD-7.09%
32.72 MUSD+4.15%
31.41 MUSD+4.01%
30.20 MUSD+16.92%
25.83 MUSD-20.47%
32.48 MUSD-60.86%
82.98 MUSD+41.24%
58.75 MUSD+128.42%
25.72 MUSD+48.50%
17.32 MUSD+76.37%
9.82 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Total Operating Expenses of Clearside Biomedical is 30.40 M USD in 2024.

Total Operating Expenses of Clearside Biomedical changed from 32.72 M USD to 30.40 M USD, representing a -7.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Clearside Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Clearside Biomedical

All Key Metrics — Clearside Biomedical